Publications

I am a co-author on over 50 peer reviewed papers and a number of conference abstracts. I maintain a list of all papers and published abstracts on Google Scholar and ORCID.org. As of September 2019 my publications have had 2269 citations and my H-index is 25. An official list of trials publications is maintained at University of Sydney Faculty of Medicine.

I maintain a record of peer-review activities (for journals) via Publons.

Highlighted

Brown, C. Barron, T. I. Bennett, K. MacDonald, D. Dwane, F. Sharp,L. 2015. Generalisability of pharmacoepidemiological studies using restricted prescription data  Irish Journal of Medical Science

Pujade-Lauraine, E; Wagner, U; Aavall-Lundqvist, E; Gebski, V; Heywood, M; Vasey, P.A; Volgger, B; Vergote, I; Pignata, S; Ferrero, A; Sehouli, J; Lortholary, A; Kristensen, G; Jackisch, C; Joly, F; Brown, Chris; Le Fur, N; Du Bois, A, 2010. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse  Journal of Clinical Oncology 28(20):3323-3329

Lee, Brown, Gralla, Hirsh, Thongprasert, Tsai, Tan, Ho, Chu, Zaatar, Osorio Sanchez, Vu, Au, Inoue, Lee, Gebski, Yang, 2013. Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis JNCI Journal of the National Cancer Institute.

Dahlen, Tracy, Tracy, Bisits, Brown, Thornton, 2014. Rates of obstetric intervention and associated perinatal mortality and morbidity among low-risk women giving birth in private and public hospitals in NSW (2000-2008): a linked data population-based cohort study BMJ Open.

All Publications

Barron,; Ian, Chris Brown Thomas, 2016. Caution in time-to-event models where a pre-event state modifies time-varying exposure  Figshare.

Brown, Chris, 2016. The Relationship between Dyslipidemia and Acute Axonal Function in Type 2 Diabetes Mellitus In Vivo.  

Brown, Chris, 2015. Treatment Strategies and Survival of Older Breast Cancer Patients - An International Comparison between the Netherlands and Ireland.  

Sharp,; Linda, Chris Brown Thomas Ian Barron Kathleen Bennett, 2015. Associations between pre- and post-diagnostic use of beta-blockers and ovarian cancer survival  Figshare.

Brown, Chris, 2015. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.  

Brown, Chris, 2015. A meta-analytic approach to large scale competing risks regression  Figshare.

Brown, Chris, 2015. De-novo post-diagnosis aspirin use and mortality in women with stage I-III breast cancer.  

Brown, Chris, 2015. Generalisability of pharmacoepidemiological studies using restricted prescription data.  

Brown, Chris, 2015. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.  

Sharp,; Linda, Chris Brown Harry Comber, 2014. Marital status associated with ovarian cancer stage, treatment and outcomes?  Figshare.

Barron,; Ian, Chris Brown Linda Sharp Kathleen Bennett Thomas, 2014. Bias in prescription data of the Irish ovarian cancer population  Figshare.

Brown, Chris, 2014. Rates of obstetric intervention and associated perinatal mortality and morbidity among low-risk women giving birth in private and public hospitals in NSW (2000-2008): a linked data population-based cohort study.  

Sharp,; Linda, Chris Brown Thomas Ian Barron Kathleen Bennett, 2014. Using routine prescribing data to identify comorbidities in cancer patients  Figshare.

Brown, Chris, 2014. Patterns of care in adult medulloblastoma: results of an international online survey.  

Brown, Chris, 2014. Smoking at diagnosis is an independent prognostic factor for cancer-specific survival in head and neck cancer: findings from a large, population-based, study.  

Fox, P.; Hudson, M.; Brown, Chris; Lord, S.; Gebski, V.; De Souza, P.; Lee, C.K., 2013. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer  British Journal of Cancer 109(1):147-153

Nowak, A.K.; Brown, Chris; Millward, M.J.; Creaney, J.; Byrne, M.J.; Hughes, B.; Kremmidiotis, G.; Bibby, D.C.; Leske, A.F.; Mitchell, P.L.R.; Pavlakis, N.; Boyer, M.; Stockler, M.R., 2013. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma  Lung Cancer 81(3):422-427

Lee, C.K.; Simes, R.J.; Brown, Chris; Gebski, V.; Pfisterer, J.; Swart, A.-M.; Berton-Rigaud, D.; Plante, M.; Skeie-Jensen, T.; Vergote, I.; Schauer, C.; Pisano, C.; Parma, G.; Baumann, K.; Ledermann, J.A.; Pujade-Lauraine, E.; Bentley, J.; Kristensen, G.; Belau, A.; Nankivell, M.; Canzler, U.; Lord, S.J.; Kurzeder, C.; Friedlander, M., 2013. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer  Annals of Oncology 24(4):937-943

Lee, C.K.; Brown, Chris; Gralla, R.J.; Hirsh, V.; Thongprasert, S.; Tsai, C.-M.; Tan, E.H.; Ho, J.C.-M.; Chu, D.T.; Zaatar, A.; Osorio Sanchez, J.A.; Vu, V.V.; Au, J.S.K.; Inoue, A.; Lee, S.M.; Gebski, V.; Yang, J.C.-H., 2013. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis  Journal of the National Cancer Institute 105(9):595-605

Priddis, H.; Dahlen, H.G.; Schmied, V.; Sneddon, A.; Kettle, C.; Brown, Chris; Thornton, C., 2013. Risk of recurrence, subsequent mode of birth and morbidity for women who experienced severe perineal trauma in a first birth in New South Wales between 2000 -2008: A population based data linkage study  BMC Pregnancy and Childbirth 13.

Brown, Chris, 2013. Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.  

Dahlen, H.; Priddis, H.; Schmied, V.; Sneddon, A.; Kettle, C.; Brown, Chris; Thornton, C., 2013. Trends and risk factors for severe perineal trauma during childbirth in New South Wales between 2000 and 2008: A population-based data study  BMJ Open 3.

Clarke, S.J.; Yip, S.; Brown, Chris; Van Hazel, G.A.; Ransom, D.T.; Goldstein, D.; Mark Jeffrey, G.; Tebbutt, N.C.; Buck, M.; Lowenthal, R.M.; Boland, A.; Gebski, V.; Zalcberg, J.; John Simes, R., 2012. Erratum: Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; Results of a randomised phase II study (DaVINCI) and meta-analysis (European Journal of Cancer (2011) 47:12 (1826-1836))  European Journal of Cancer 48.

Brown, Chris, 2012. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial  Annals of Oncology 23(5):1185-1189

Wagner, U.; Marth, C.; Largillier, R.; Kaern, J.; Brown, Chris; Heywood, M.; Bonaventura, T.; Vergote, I.; Piccirillo, M.C.; Fossati, R.; Gebski, V.; Lauraine, E.P., 2012. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients  British Journal of Cancer 107(4):588-591

Alexandre, J.; Brown, Chris; Coeffic, D.; Raban, N.; Pfisterer, J.; Mäenpää, J.; Chalchal, H.; Fitzharris, B.; Volgger, B.; Vergote, I.; Pisano, C.; Ferrero, A.; Pujade-Lauraine, E., 2012. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: Experience of the GCIG CALYPSO trial  British Journal of Cancer 106(4):633-637

Brundage, M.; Gropp, M.; Mefti, F.; Mann, K.; Lund, B.; Gebski, V.; Wolfram, G.; Reed, N.; Pignata, S.; Ferrero, A.; Brown, Chris; Eisenhauer, E.; Pujade-Lauraine, E., 2012. Health-related quality of life in recurrent platinum-sensitive ovarian cancer-results from the calypso trial  Annals of Oncology 23(8):2020-2027

Dahlen, H.G.; Tracy, S.; Tracy, M.; Bisits, A.; Brown, Chris; Thornton, C., 2012. Rates of obstetric intervention among low-risk women giving birth in private and public hospitals in NSW: A population-based descriptive study  BMJ Open 2.

Goldstein, D.; Spry, N.; Cummins, M.M.; Brown, Chris; Van Hazel, G.A.; Carroll, S.; Selva-Nayagam, S.; Borg, M.; Ackland, S.P.; Wratten, C.; Shapiro, J.; Porter, I.W.T.; Hruby, G.; Horvath, L.; Bydder, S.; Underhill, C.; Harvey, J.; Gebski, V.J., 2012. The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer  British Journal of Cancer 106(1):61-69

Ong, K.L.; Rye, K.-A.; O&aposConnell, R.; Jenkins, A.J.; Brown, Chris; Xu, A.; Sullivan, D.R.; Barter, P.J.; Keech, A.C., 2012. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes  Journal of Clinical Endocrinology and Metabolism 97(12):4701-4708

Goldstein, D.; Gainford, M.C.; Brown, Chris; Tebbutt, N.; Ackland, S.P.; Van Hazel, G.; Jefford, M.; Abdi, E.; Selva-Nayagam, S.; Gebski, V.; Miller, D.; Shannon, J., 2011. Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas  Cancer Chemotherapy and Pharmacology 67(3):519-525

Lee, C.K.; Friedlander, M.; Brown, Chris; Gebski, V.J.; Georgoulopoulos, A.; Vergote, I.; Pignata, S.; Donadello, N.; Schmalfeldt, B.; Delva, R.; Mirza, M.R.; Sauthier, P.; Pujade-Lauraine, E.; Lord, S.J.; Simes, R.J., 2011. Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer  Journal of the National Cancer Institute 103(17):1338-1342

Lee, C.K.; Gurney, H.; Brown, Chris; Sorio, R.; Donadello, N.; Tulunay, G.; Meier, W.; Bacon, M.; Maenpaa, J.; Petru, E.; Reed, N.; Gebski, V.; Pujade-Lauraine, E.; Lord, S.; Simes, R.J.; Friedlander, M., 2011. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer  British Journal of Cancer 105(3):360-365

Blinman, P.; McLachlan, S.-A.; Nowak, A.K.; Duric, V.M.; Brown, Chris; Wright, G.; Millward, M.; Fong, K.; Stockler, M.R., 2011. Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?  Lung Cancer 72(2):213-218

McIntyre, S.; Badawi, N.; Brown, Chris; Blair, E., 2011. Population case-control study of cerebral palsy: Neonatal predictors for low-risk term singletons  Pediatrics 127.

Brown, Chris, 2011. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].  

Kurtz, J.E.; Kaminsky, M.C.; Floquet, A.; Veillard, A.S.; Kimmig, R.; Dorum, A.; Elit, L.; Buck, M.; Petru, E.; Reed, N.; Scambia, G.; Varsellona, N.; Brown, Chris; Pujade-lauraine, E., 2011. Ovarian cancer in elderly patients: Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: A gynecologic cancer intergroup (GCIG) CALYPSO sub-study  Annals of Oncology 22(11):2417-2423

Lee, C.K.; Simes, R.J.; Brown, Chris; Lord, S.; Wagner, U.; Plante, M.; Vergote, I.; Pisano, C.; Parma, G.; Burges, A.; Bourgeois, H.; Högberg, T.; Bentley, J.; Angleitner-Boubenizek, L.; Ferrero, A.; Richter, B.; Hirte, H.; Gebski, V.; Pfisterer, J.; Pujade-Lauraine, E.; Friedlander, M., 2011. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer  British Journal of Cancer 105(8):1144-1150

Ananda, S.; Nowak, A.K.; Cher, L.; Dowling, A.; Brown, Chris; Simes, J.; Rosenthal, M.A., 2011. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy  Journal of Clinical Neuroscience 18(11):1444-1448

Pujade-Lauraine, E.; Wagner, U.; Aavall-Lundqvist, E.; Gebski, V.; Heywood, M.; Vasey, P.A.; Volgger, B.; Vergote, I.; Pignata, S.; Ferrero, A.; Sehouli, J.; Lortholary, A.; Kristensen, G.; Jackisch, C.; Joly, F.; Brown, Chris; Le Fur, N.; Du Bois, A., 2010. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse  Journal of Clinical Oncology 28(20):3323-3329

Publication list retrieved from ORCiD using ImpactPubs

.